摘要：
The principle of pharmacogenetics and pharmacogenomics (PGx) in health research is not new. However, pursuance thereof has regained momentum in the 21 st century. Despite the apparent demand to respond to adverse drug reactions (ADRs), both the national and international medico-legal frameworks have struggled to determine the place of PGx within the scientific and medical arena. It is against such a background that the study sought to explore the medico-legal issues relating to pharmacogenomics and the development of personalised medicine in the context of the human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome (AIDS) in South Africa. The methodology employed in this thesis involves a critical and comparative examination of the international instruments and their monopolistic influences on the multinational pharmaceutical conglomerates (also known as "Big- Pharma") regarding the manufacturing of antiretroviral drugs (ARVs). PGx, which relies on genetic variability, facilitates the development of personalised medicine where adverse drug reactions (ADRs) may be minimised. Currently, PGx in the South African context, and, in respect to people living with HIV, is approached in a fragmented manner. The South African approach to genomic research is caught between the provisions of section 27 of the Constitution's debate concerning the availability of health resources, the protection of individuals and communities, as well as competing human rights issues. Biobanks, necessary for PGx to develop, are increasingly required to store large genetic information for purposes of interpretation and evaluation of ADRs associated with the ARVs. Since genes are personal identifiers, data privacy has started to dominate the international genomic research arena and therefore, invokes added complexities relating to informed consent. Drawing on the English and the Canadian approaches to PGx, the thesis identifies some useful principles and practices for the South
